Status:
COMPLETED
Enhancing Use of Hydroxyurea In Sickle Cell Disease Using Patient Navigators
Lead Sponsor:
Virginia Commonwealth University
Collaborating Sponsors:
Eastern Virginia Medical School
Children's Hospital of The King's Daughters
Conditions:
Sickle Cell Disease
Eligibility:
All Genders
15+ years
Phase:
NA
Brief Summary
Multi-phase, patient navigator-based program in the Richmond and Tidewater regions of Virginia to demonstrate: 1. the feasibility of using patient navigators to improve the percentage of children and...
Detailed Description
The state of Virginia, including the Virginia Department of Health and three academic medical centers and one federally qualified health center, plans a two-phase demonstration, first of improvement i...
Eligibility Criteria
Inclusion
- PHASE I:
- Patient Self Report of Sickle Cell Disease (Genotypes: Hb SS, SC, SBoThal, SB+Thal)
- 15 years or older
- Virginia resident
Exclusion
- Visited one of a pre-selected list of sickle cell specialists in Virginia within the last 6 months
- PHASE II:
- Inclusion Criteria:
- Sickle Cell Disease (SCD) patient (Genotypes: SS or SBoThal)
- Eligible for Hydroxyurea (according to NIH guidelines)
- 15 years or older
- Virginia resident
Key Trial Info
Start Date :
October 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2018
Estimated Enrollment :
353 Patients enrolled
Trial Details
Trial ID
NCT02197845
Start Date
October 1 2012
End Date
December 31 2018
Last Update
June 2 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Virginia Commonwealth University
Richmond, Virginia, United States, 23298